Cardiovascular Health

According to the World Health Organization, cardiovascular disease is the leading global cause of death among men and women, accounting for an estimated 17.5 million deaths worldwide each year.

Patients with atrial fibrillation and end-stage renal disease may face a greater risk of all-cause bleeding without reducing strokes in Warfarin.

This study assesses comparative resource use for patients given a new diagnosis of nonvalvular atrial fibrillation treated with dabigatran or warfarin in a real-world setting.

Little information exists regarding the benefit of bridging warfarin among patients with atrial fibrillation. The best available evidence suggests that this common practice may increase the risk of bleeding without providing any efficacy benefit.

Alcohol consumption may cause heart damage that leads to atrial fibrillation.

Top news of the day from across the health care landscape.

The FDA recently approved Aralez Pharmaceuticals' Yosprala, a once-daily, fixed-dose combination of the antiplatelet agent aspirin and the proton pump inhibitor omeprazole.

Recent study results suggest patients don't know enough about warfarin, which could have potentially dangerous consequences.

Treatment with edoxaban was as efficient as warfarin, but quicker.

Pharmacokinetics of anticoagulant tecarfarin not compromised by renal function as seen with warfarin.

Warfarin may increase bleeding risk more than non-vitamin K antagonist oral anticoagulants.

Antibody prevents blood clots and excessive bleeding to improve treatment of atrial fibrillation.

Pharmacokinetics of tecarfarin were not compromised by renal function like it was with warfarin.

Although fixed daily doses of NOACs have demonstrated favorable efficacy and safety compared with warfarin, the impact of worsening renal function on these medications over time hasn't been evaluated.

This study seeks to determine the economic effects of warfarin discontinuation in patients with nonvalvular atrial fibrillation.

Medicare requires a consultation with a non-implantation doctor prior to beneficiaries receiving the Watchman.

Top news of the day from across the health care landscape.

Sepsis leads to approximately 1 million hospitalizations in the United States yearly, and atrial fibrillation is the most common arrhythmia to complicate its course.

This article summarizes recent literature evaluting the risks and benfits of resuming anticoaguation in atrial fibrillation patients who experience gastrointestinal bleeding.

Although it was discovered in the early 1900s, unfractionated heparin remains one of the most commonly used anticoagulants in clinical practice today.

Diabetic macular oedema could be reduced by the cardiovascular drug darapladib.

The Watchman prevents blood clots from forming in the left atrial appendage and prevents strokes.

Cardiovascular disease accounts for 30% of all deaths worldwide, and it is not just 1 disease.

Generic dofetilide capsules approved to treat atrial fibrillation and atrial flutter.

Approximately 45% of female patients with atrial fibrillation did not receive blood thinning treatment to prevent strokes.

Women with new-onset atrial fibrillation found to have a high risk of developing cancer in the first 3 months.

The American College of Cardiology, the American Heart Association, and the Heart Failure Society of America have updated heart failure guidelines.

Atrial fibrillation, the most common cardiac arrhythmia, is strongly associated with increased morbidity and mortality and has become a major global public health challenge.

Pharmacists can help evaluate and address adherence barriers among patients taking medications for cardiovascular disease.

Despite advances in preventative drug therapy, cardiovascular disease remains the leading cause of death in the United States.